16 research outputs found
Recommended from our members
Nurses perspectives on their developing roles in hyper acute stroke setting and within the multidisciplinary team
Healthcare for London in collaboration with the Cardiac and Stroke Network and local NHS Trusts in London have introduced hyper acute stroke units (HASUs).
HASU has been defined by Healthcare for London:
• World-class stroke treatment 24-hours a day
• Rapid assessment
• Arrival on a specialist stroke ward within two hours of arrival to the emergency department (ED)
• CT scan within 30 minutes of arrival to the ED
• Thrombolysis if appropriate within 30 minutes of arrival to the ED
• 24/7 monitoring in a high dependency bed
• Multidisciplinary specialist stroke team, including consultants, nurses and therapists.
Imperial College Healthcare NHS Trust opened a HASU on 1st February 2010.
However, there is a lack of information on the nurses’ perspectives on their developing roles in the hyper acute stroke setting and within the multidisciplinary team.
The aim of this study was to explore nurses’ perspectives on their developing roles within the hyper acute stroke setting and their role within the multidisciplinary team
Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis
Despite achieving sustained virologic response (SVR) to hepatitis C virus (HCV) therapy, there remains a post liver transplantation population with advanced fibrosis/cirrhosis. Emricasan is an orally active, pan-caspase inhibitor that suppresses apoptosis and inflammation, potentially decreasing hepatic inflammation and fibrosis. We aimed to determine the safety and efficacy of emricasan (IDN-6556-07) in a double-blind, randomized, placebo-controlled, multicenter study in reducing or preventing the progression of hepatic fibrosis in HCV liver transplant recipients with residual fibrosis or cirrhosis after achieving SVR. A total of 64 participants were randomly assigned to receive 25 mg twice daily of emricasan or placebo in a 2:1 ratio for 24 months. 41 participants were randomly assigned to emricasan and 23 to placebo; 32 participants in the emricasan group (78.0%) and 19 who took a placebo (82.6%) completed the study. There was no difference in the primary endpoint (Ishak fibrosis stages F2-F5, improvement in fibrosis or stability; Ishak fibrosis stage F6, improvement) between the emricasan (77.1%) and placebo groups (74.1%); P = NS. There was no difference between the emricasan (54.5%) and placebo (60.7%) arms in the rate of fibrosis improvement alone. However, those in the prespecified F3 to F5 subgroup had higher rates of stability or improvement in fibrosis in the emricasan group (95.2%) compared with placebo (54.6%) (P = 0.01). The tolerability and safety profiles were similar in both groups. In conclusion, overall stability in the Ishak fibrosis stage was similar between emricasan and placebo groups at 24 months. However, there was improvement and/or stability in fibrosis stage in the prespecified F3 to F5 subgroup with emricasan versus placebo, suggesting that patients with moderate fibrosis may benefit with emricasan